Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
214450KOSDAQ·Aug 12, 2025
Stellar 2Q performance; 2H to be even better
Mirae Asset Securities published a company analysis report on PharmaResearch (214450) titled "Stellar 2Q performance; 2H to be even better".
Summary
Covers PharmaResearch (214450).
Covered stock
More on 214450
Diversification benefits set to buildMirae Asset Securities · Aug 18, 2026Lasting Value of OriginalsKB Securities · Jun 19, 2026Bottom confirmed; Rejuran remains resilientMirae Asset Securities · May 11, 2026Three key factors to weighMirae Asset Securities · Feb 05, 2026An inevitable valuation resetMirae Asset Securities · Nov 12, 2025Rejuran to remain a staple in aesthetic medicineMirae Asset Securities · Oct 20, 2025From regional champion to global contenderMirae Asset Securities · Jul 24, 2025Rejuran��s rapid growth continuesMirae Asset Securities · May 21, 2025Rejuran With Higher Expectations (full ver.)Korea IR Service · Apr 22, 2025Global leader in skin boostersMirae Asset Securities · Feb 11, 2025